13.1 Sterile, Nonsterile & Hazardous Compounding

13.1 Sterile, Nonsterile & Hazardous Compounding

Quick Answer: Minnesota pharmacies that compound must follow USP <795> for nonsterile preparations and USP <797> for sterile preparations under Rule 6800.3300. USP <800> addresses hazardous drugs (containment, PPE, engineering controls). Federally, DQSA §503A is traditional, largely patient-specific pharmacy compounding under state/USP rules; §503B is an FDA-registered outsourcing facility under CGMP that may produce larger batches (often for office stock). Anticipatory compounding is limited and history-based—not manufacturing.

NABP Area 4 (Pharmacy Operations, ~21%) expressly includes compounding. The MPJE does not ask you to recite full USP monographs. It does ask you to recognize which standard applies, what environment and PPE are required conceptually, who may compound under which federal pathway, and when a practice has crossed into unlawful manufacturing or unsafe sterile/hazardous handling.

The Three USP Pillars (Exam Map)

Treat Minnesota as adopting the USP practice standard for sterile and nonsterile work in licensed pharmacies. Board inspection vignettes that say “noncompliant sterile suite” or “no competency documentation” map back to <797>/<795> systems, not to a free-form “pharmacy custom.”

USP <795> Nonsterile — Competency & Environment Concepts

Nonsterile compounding still requires a quality system, not kitchen improvisation:

1. Personnel competency. Compounders need training and documented competency appropriate to the preparation (calculations, equipment use, technique, cleaning, documentation).
2. Designated space. Compounding areas should be clean, orderly, and suitable—segregated from ordinary traffic and contamination sources as the chapter expects for the type of work.
3. Components & formula control. Use appropriate bulk ingredients (identity/quality), master formulas or equivalent documentation, and process records for non-simple preparations.
4. Equipment. Balances, mortars, ointment mills, and measuring devices must be clean, calibrated/maintained as appropriate, and used correctly.
5. Beyond-use dating (BUD). Assign a BUD based on the chapter’s stability/risk framework and professional judgment—not an arbitrary multi-year shelf life.
6. Labeling & counseling readiness. The finished container must support safe use; patients need information on use, storage, and hazards of the preparation.

Exam framing: nonsterile ≠ “anything goes.” If a stem describes crushed tablets mixed on a cluttered lunch counter with no records, the failure is process and environment, not merely “missing a fancy cleanroom.”

USP <797> Sterile — Categories, Environment & Engineering Controls

Sterile compounding is where MPJE vignettes get serious because patient harm from contamination is high. Think in systems, not brand names of hoods.

Core concepts

• Aseptic technique is mandatory for personnel who prepare CSPs (compounded sterile preparations).
• Primary engineering control (PEC) — the ISO-classified work zone where critical sites are exposed (e.g., laminar airflow workbench, compounding aseptic isolator). Air quality and airflow protect the critical site.
• Secondary engineering control (SEC) — the cleanroom suite or segregated compounding area that houses the PEC and supports pressure cascades, cleaning, and gowning discipline.
• Risk / category thinking. Modern <797> organizes sterile work by categories (and related immediate-use concepts) that drive facility design, environmental monitoring, sterility testing expectations, and maximum BUDs. Higher-risk or longer-BUD sterile work needs more stringent environments and quality controls.
• Immediate-use concepts exist for urgent situations with tight time limits and process constraints—do not treat “stat” as permission to skip all controls forever.
• Competency. Media-fill (aseptic technique validation), gloved fingertip sampling concepts, and ongoing training are classic sterile-quality themes on exams.
• Environmental monitoring & cleaning. Viable/nonviable monitoring concepts, surface sampling themes, and defined cleaning/disinfection programs support ongoing control of the environment.

Hospital/parenteral operational link

Minnesota hospital pharmaceutical service rules reinforce sterile admixture discipline: Rule 6800.7520 requires written precautionary measures for safe parenteral admixture, limits who may prepare admixtures, and requires sterile admixtures to be prepared under 6800.3300, subp. 2 (USP <797>) and labeled under 6800.7900. That is the operations bridge between USP theory and Minnesota facility practice (detailed further in §13.2).

USP <800> Hazardous Drugs — Containment Mindset

USP <800> is about hazardous drugs (HDs)—antineoplastics and other agents that pose occupational or environmental risk (carcinogenicity, reproductive toxicity, organ toxicity at low doses, genotoxicity, etc.). NIOSH maintains lists that institutions use to identify HDs; exams care that you recognize the need for special handling, not that you quote every NIOSH table row.

High-yield control stack:

Exam traps:

• Compounding a hazardous chemo agent on an open benchtop without containment → USP <800> / sterile-hazardous failure.
• Using the same PPE path for hazardous and non-hazardous work without decontamination discipline → cross-contamination risk.
• Storing hazardous bulk powders next to food or non-HD stock without segregation → facility control failure.

Minnesota hospital policies under Rule 6800.7510 explicitly require pharmaceutical service policies covering preparation, use, and disposal of chemotherapy drugs and compounded sterile/nonsterile products—another signal that hazardous and sterile compounding are policy-level PIC duties, not optional “advanced” extras.

DQSA: 503A Traditional Pharmacy vs 503B Outsourcing Facility

The Drug Quality and Security Act (DQSA) clarified federal compounding after large-scale compounding disasters. Two pathways matter constantly on the MPJE:

Section 503A — Traditional pharmacy compounding

• Compounded primarily for an identified individual patient pursuant to a valid prescription (or limited anticipatory compounding—see below).
• Performed by a licensed pharmacist in a state-licensed pharmacy (or by a licensed physician in allowed settings).
• Generally regulated by the state board with USP compounding standards as the quality framework.
• Exempt from full new drug approval, certain labeling rules, and CGMP manufacturing requirements if 503A conditions are met.
• Not a vehicle for large-scale production of essentially copies of commercially available products, for drugs on the FDA “difficult to compound” or withdrawn-for-safety lists, or for wholesale-style distribution.

Minnesota mirrors the bulk-substance and “essentially a copy” constraints in Minn. Stat. §151.253 (covered in §13.2).

Section 503B — Outsourcing facilities

• Register with FDA as an outsourcing facility (also defined in Minn. Stat. §151.01, subd. 14b).
• May compound large batches and supply products for office use / healthcare facility stock without a patient-specific prescription in many cases.
• Must comply with current good manufacturing practice (CGMP)—a higher manufacturing bar than USP pharmacy compounding alone.
• Subject to FDA inspection and federal reporting/registration duties; state licensure overlays may still apply depending on activity and location.

Exam reflex: hospital wants bulk sterile bags stocked without patient names → think 503B/outsourcing (or manufacturer), not “community pharmacy anticipatory compounding of unlimited inventory.”

Anticipatory Compounding (Federal + Minnesota Concept)

Anticipatory compounding is preparation of a limited supply before receipt of a specific prescription, based on a history of orders and an established relationship—then dispensed only against later valid patient-specific orders. Under Minn. Stat. §151.01, subd. 36, anticipatory compounding is a supply sufficient for the pharmacy’s short-term anticipated need for filling prescription drug orders—not wholesale distribution. Extemporaneous compounding (subd. 37) is compounding after a patient-specific order is issued.

Federal 503A similarly allows only limited quantities before the Rx, with history and relationship conditions. Unlimited “make a thousand tubes for walk-ins we might get” is manufacturing territory.

Competency Categories You Must Keep Straight

On test day, classify the vignette quickly:

1. Nonsterile ordinary → <795> space, process, BUD, records.
2. Sterile ordinary → <797> PEC/SEC, aseptic competency, category/BUD discipline.
3. Hazardous → <800> containment + PPE on top of sterile/nonsterile rules.
4. Scale & purpose → patient-specific 503A vs 503B outsourcing vs manufacturing license (§151.252 / §151.253 gate).
5. Who is supervising → pharmacist oversight, technician compounding under supervision, certification before release (links to ratios/certification chapters).

Study Checklist

1. Recite 6800.3300: nonsterile = <795>; sterile = <797>.
2. Contrast 503A (patient-specific, state/USP) vs 503B (FDA, CGMP, batch/office stock).
3. List HD controls: C-PEC, C-SEC, PPE, spill, segregation.
4. Define anticipatory compounding as limited, history-based, short-term need—not wholesale.
5. Connect hospital sterile admixture policies to 6800.7520 + 6800.3300.

If you can place any vignette into the correct USP chapter and federal pathway in ten seconds, you are ready for Area 4 compounding items.